Lilly(Eli) & Co [NYSE: LLY] price plunged by -0.88 percent to reach at -$5.56. The company report on January 10, 2024 at 7:30 PM that Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene.
Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rights.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Henlius to facilitate clinical development for the initiated Phase 3 MRCT (ELAINE-3) of lasofoxifene in the territory.
The one-year LLY stock forecast points to a potential upside of 3.85. The average equity rating for LLY stock is currently 1.69, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Lilly[Eli] & Co [LLY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $648.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 1.69. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Daiwa Securities have made an estimate for Lilly(Eli) & Co shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 21, 2023.
The Average True Range (ATR) for Lilly(Eli) & Co is set at 13.73, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 18.45. The Price to Book ratio for the last quarter was 52.76, with the Price to Cash per share for the same quarter was set at 2.63. Price to Free Cash Flow for LLY in the course of the last twelve months was 181.85 with Quick ratio for the last quarter at 0.82.
LLY Stock Performance Analysis:
Lilly(Eli) & Co [LLY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.09. With this latest performance, LLY shares gained by 8.97% in over the last four-week period, additionally plugging by 37.43% over the last 6 months – not to mention a rise of 74.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 59.26, with the RSI for the last a single of trading hit 57.60, and the three-weeks RSI is set at 58.55 for Lilly(Eli) & Co [LLY]. The present Moving Average for the last 50 days of trading for this stock 597.44, while it was recorded at 633.09 for the last single week of trading, and 513.64 for the last 200 days.
Insight into Lilly[Eli] & Co Fundamentals:
Lilly(Eli) & Co’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.82 and a Current Ratio set at 1.05.
LLY Stock EPS
With the latest financial reports released by the company, Lilly(Eli) & Co posted 2.09/share EPS, while the average EPS was predicted by analysts to be reported at 1.78/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lilly(Eli) & Co go to 28.72%.
Lilly[Eli] & Co [LLY] Institutonal Ownership Details
The top three institutional holders of LLY stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in LLY stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in LLY stock with ownership which is approximately 5.8325%.
